EpiCord Expandable Placental Allograft Is Launched by MiMedx

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

September 14, 2020

EpiCord Expandable Placental Allograft has been launched. The news was announced today by MiMedx.

EpiCord Expandable Placental Allograft allows the allograft to cover up to twice the surface area once expanded. This new placental tissue allograft provides healthcare professionals an additional option to support the advanced wound care needs of their patients with larger, chronic, and hard-to-heal wounds.

“There is growing demand for advanced interventions in the treatment of chronic wounds,” said Dr. Bill Tettelbach, MiMedx Principal Medical Officer. “Many are unaware that about 20 percent of moderate-to-severe diabetic foot ulcers lead to amputation. When people with diabetes have a non-traumatic below the knee amputation, their mortality rate can exceed 70 percent at five years. Treatment of these patients is aimed at healing the wound, saving their limb and improving their quality of life. Healthcare professionals are looking for added versatility when addressing larger, hard-to-heal wounds, and the new EpiCord Expandable provides a versatile and flexible option to help meet this urgent patient need for those who may require specific interventions to restart the healing process.”

More than 30 million Americans are living with diabetes and the numbers continue to increase. Of those with diabetes, 2.9 million of them suffer from chronic wounds. Data show that the cost of treating chronic wounds in the United States is rising sharply, exceeding an estimated $28 billion annually.

Timothy R. Wright, MiMedx Chief Executive Officer, commented, “As a pioneer in the development of placental tissue technology, MiMedx is constantly improving our knowledge of placental science – as a unique biological system that supports growth and healing – to elevate the standard of care and help bring hope and relief to the millions suffering with chronic and hard-to-heal wounds. With an aging population and rapidly growing number of people with diabetes, new applications of placental-tissue science like EpiCord Expandable will help to meet public health needs and advance the field.”



Subscribe to Medical Device News Magazine

Related Articles